Promising Early Data from INVINCIBLE-4 Study Could Boost INT230-6's Outlook
Preliminary results from the INVINCIBLE-4 Study reveal that patients receiving INT230-6 show significantly higher pathological complete response rates and fewer severe adverse events compared to those receiving standard of care. With the submission of a protocol amendment to Swiss authorities for resumed enrollment, there is potential for accelerated pathways to approval, which could positively impact investor sentiment towards INTS.
View signal analysis